MedTrace Logo

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

NCT00226980 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-04-14

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.

Conditions

  • Kidney Neoplasms

Interventions

DRUG

Thalidomide

DRUG

Capecitabine

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2005-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226980 on ClinicalTrials.gov